Sophia Genetics SA
SOPH4.800USD
+0.200+4.35%
終値 02/06, 16:00（ET）15分遅れの株価
325.67M時価総額
損失額直近12ヶ月PER
詳細情報 Sophia Genetics SA 企業名
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Sophia Genetics SAの企業情報
企業コードSOPH
会社名SOPHiA GENETICS SA
上場日Jul 23, 2021
最高経営責任者「CEO」Camblong (Jurgi)
従業員数423
証券種類Ordinary Share
決算期末Jul 23
本社所在地La Piece 12
都市ROLLE
証券取引所NASDAQ OMX - NASDAQ BASIC
国Switzerland
郵便番号CH-1180
電話番号41216941060
ウェブサイトhttps://www.sophiagenetics.com/
企業コードSOPH
上場日Jul 23, 2021
最高経営責任者「CEO」Camblong (Jurgi)
Sophia Genetics SAの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+194164.00%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+48309.00%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-17644.00%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+48309.00%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+59409.00%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+66596.00%
Dr. Philippe Menu, M.D., Ph.D.
Dr. Philippe Menu, M.D., Ph.D.
Chief Medical Officer and Chief Product Officer
Chief Medical Officer and Chief Product Officer
39.60K
-2144.00%
Mr. Daan Van Well
Mr. Daan Van Well
Chief Legal and Compliance Officer
Chief Legal and Compliance Officer
--
--
Ms. Manuela Da Silva Valente
Ms. Manuela Da Silva Valente
Chief People Officer
Chief People Officer
--
--
Dr. Tomer Berkovitz, Ph.D.
Dr. Tomer Berkovitz, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+194164.00%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+48309.00%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-17644.00%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+48309.00%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+59409.00%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+66596.00%
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
Rest of EMEA
6.63M
34.09%
France
3.12M
16.01%
United States
2.62M
13.45%
Italy
2.51M
12.89%
Spain
1.46M
7.48%
他の
3.13M
16.08%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sun, Feb 1
更新時刻: Sun, Feb 1
株主統計
種類
株主統計
株主統計
比率
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
他の
61.13%
株主統計
株主統計
比率
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
他の
61.13%
種類
株主統計
比率
Investment Advisor/Hedge Fund
16.43%
Venture Capital
13.08%
Family Office
10.36%
Investment Advisor
8.51%
Individual Investor
6.43%
Hedge Fund
1.06%
Bank and Trust
0.46%
Research Firm
0.06%
Pension Fund
0.03%
他の
43.58%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
81
26.90M
39.65%
-12.60M
2025Q3
76
26.89M
39.64%
-8.96M
2025Q2
89
36.69M
54.29%
-200.15K
2025Q1
93
36.63M
54.82%
-389.48K
2024Q4
93
32.50M
49.36%
-965.83K
2024Q3
91
34.60M
52.08%
+657.87K
2024Q2
92
32.44M
48.93%
+1.33M
2024Q1
93
31.91M
48.51%
+375.11K
2023Q4
91
30.61M
46.76%
-676.23K
2023Q3
91
30.34M
46.61%
-4.34M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Alychlo NV
6.99M
10.31%
--
--
Feb 15, 2025
Generation Investment Management LLP
6.79M
10.01%
--
--
Sep 30, 2025
aMoon Fund
5.51M
8.12%
+577.36K
+11.70%
Feb 15, 2025
Akre Capital Management, LLC
3.72M
5.48%
--
--
Sep 30, 2025
Balderton Capital (UK) LLP
3.36M
4.96%
--
--
Feb 15, 2025
Camblong (Jurgi)
2.65M
3.91%
+194.16K
+7.89%
Feb 15, 2025
Banque Pictet & Cie S.A.
2.21M
3.25%
--
--
Sep 30, 2025
Alta Wealth Advisors LLC
1.41M
2.08%
+1.41M
--
Sep 30, 2025
Principal Global Investors (Equity)
1.39M
2.05%
-8.95K
-0.64%
Sep 30, 2025
Ossipow (Vincent)
443.81K
0.65%
+48.31K
+12.21%
Feb 15, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Health Innovation Active ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Health Innovation Active ETF
比率0%
Fidelity Nasdaq Composite Index ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
